United States securities and exchange commission logo





                            April 10, 2023

       Paul A. Romness, MPH
       President and Chief Executive Officer
       OS Therapies Incorporated
       15825 Shady Grove Road, Suite 135
       Rockville, Maryland 20850

                                                        Re: OS Therapies
Incorporated
                                                            Registration
Statement on Form S-1
                                                            Filed March 31,
2023
                                                            File No. 333-271034

       Dear Paul A. Romness:

              We have reviewed your registration statement and have the
following comment. In this
       comment, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       Phase 1B Clinical Trial, page 3

   1.                                                   We note your revised
disclosure on page 69 in response to Comment 5. Please revise the
                                                        disclosure on page 3 to
highlight that no objective tumor response (complete or partial)
                                                        was observed in the
trial.
 Paul A. Romness, MPH
FirstName   LastNamePaul
OS Therapies   IncorporatedA. Romness, MPH
Comapany
April       NameOS Therapies Incorporated
       10, 2023
April 210, 2023 Page 2
Page
FirstName LastName
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Christine Torney at 202-551-3652 or Lynn Dicker at
202-551-3616 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jimmy McNamara at 202-551-7349 or Joe McCann at 202-551-6262 with any
other
questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:      Spencer G. Feldman